Constructing a Novel Prognostic Signature Based on TGF-β Signaling for Personalized Treatment in Pancreatic Adenocarcinoma

Figure 7

TIDE prediction of the efficiency to immunotherapy in TCGA-PAAD dataset. (a–d) The score of TGF-β response (a) proliferation (b) macrophage regulation (c) and wound healing (d) in two groups. Student t test was performed. (e) The percentage of positive and negative response to immunotherapy predicated by TIDE in high-risk and low-risk groups. False indicates negative response and true indicates positive response. ANOVA test was performed. (f–h) TIDE score (f), T cell dysfunction score (g) and T cell exclusion (h) score in high-risk and low-risk groups. Student t test was performed. , , , .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)